- Home
- HPK vs SNY Comparison
HPK vs SNY Comparison
Compare HPK & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HPK | SNY |
|---|---|---|
| Founded | 2019 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 104.5B |
| IPO Year | 2020 | 2001 |
Fundamental Metrics
Financial Performance| Metric | HPK | SNY |
|---|---|---|
| Price | $8.47 | $42.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.00 | ★ $58.00 |
| AVG Volume (30 Days) | 313.4K | ★ 2.1M |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | 2.30% | ★ 3.47% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $863,359,000.00 | N/A |
| Revenue This Year | N/A | $3.49 |
| Revenue Next Year | N/A | $6.10 |
| P/E Ratio | ★ N/A | $6.14 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.85 | $40.89 |
| 52 Week High | $9.13 | $52.68 |
Technical Indicators
Market Signals| Indicator | HPK | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 62.28 | 35.88 |
| Support Level | $6.45 | $42.30 |
| Resistance Level | $9.13 | $45.22 |
| Average True Range (ATR) | 0.37 | 0.59 |
| MACD | 0.01 | -0.30 |
| Stochastic Oscillator | 83.52 | 1.89 |
Price Performance
Historical ComparisonAbout HPK HighPeak Energy Inc.
HighPeak Energy Inc is an independent crude oil and natural gas exploration and production company that explores for, develops and produces crude oil, NGL, and natural gas prominently in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S. The majority of the company's revenue is derived from the Crude oil sales.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.